Exelixis (EXEL) is a publicly traded Healthcare sector company. As of May 21, 2026, EXEL trades at $49.31 with a market cap of $12.53B and a P/E ratio of 27.62. EXEL moved +2.56% today. Year to date, EXEL is +17.69%; over the trailing twelve months it is +12.49%. Its 52-week range spans $25.17 to $51.63. Analyst consensus is buy with an average price target of $47.70. Rallies surfaces EXEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for EXEL, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $49.31 |
| Market Cap | $12.53B |
| P/E Ratio | 27.62 |
| EPS | $1.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $51.63 |
| 52-Week Low | $25.17 |
| Volume | 1.84M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.17B |
| Net Income | $521.27M |
| Gross Margin | 96.49% |
11 analysts cover EXEL: 0 strong buy, 5 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.70.